Cincinnati Children's researchers report in Nature Immunology a new mechanism that controls blood cell function and several possible molecular targets for
treating myelodysplasia syndromes (MDS)-- a group of pre-malignant disorders in which bone marrow does not produce enough healthy blood cells.